The Proteasome Inhibitors Global Market Report 2023, provides comprehensive information on the proteasome inhibitors market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.
Learn More On The Proteasome Inhibitors Market’s Growth:
https://www.thebusinessresearchcompany.com/report/proteasome-inhibitors-global-market-report
The global proteasome inhibitors market is expected to grow from $1.70 billion in 2022 to $1.86 billion in 2023 at a compound annual growth rate (CAGR) of 9.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global proteasome inhibitors is expected to reach $2.62 billion in 2027 at a CAGR of 8.9%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=12251&type=smp
Increases in investments are a key trend gaining popularity in the proteasome inhibitors market. Major companies operating in the proteasome inhibitors market are investing in developing and commercializing proteasome inhibitors, which can play a significant role in advancing research and bringing new treatments to the market. For instance, in September 2022, QLi5 Therapeutics GmbH, a Germany-based developer of new-class proteasome inhibitors, received $10.96 million (EUR 10 million) of investments from SV Investment, a South Korea-based venture capital firm, and KHAN Technology Transfer Fund I, a Germany-based venture capital firm, as well as Atinum Investment Co., Ltd. and Daol Investment & Securities Co., Ltd., South Korea-based venture capital firms. This investment aims to develop novel proteasome inhibitors for treating cancer and inflammatory and autoimmune disorders. With the help of this funding, QLi5’s pipeline of very distinct proteasome inhibitors will be advanced to the beginning of clinical studies addressing multiple indications.
The proteasome inhibitors market is segmented:
1) By Product: Velcade, Kyprolis, Ninlaro, Other Products
2) By Drugs: Bortezomib, Carfilzomib, Ixazomib
3) By Indication: Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospital, Specialty Clinics, Other End-Users
North America was the largest region in the proteasome inhibitors market in 2022.
The table of contents in TBRC’s proteasome inhibitors market report includes:
1. Executive Summary
2. Proteasome Inhibitors Market Characteristics
3. Proteasome Inhibitors Market Trends And Strategies
4. Proteasome Inhibitors Market – Macro Economic Scenario
5. Global Proteasome Inhibitors Historic Market Size and Growth, 2017 – 2022, Value ($ Billion)
……………………….
32. Global Proteasome Inhibitors Market Competitive Benchmarking
33. Global Proteasome Inhibitors Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Proteasome Inhibitors Market
35. Proteasome Inhibitors Market Future Outlook and Potential Analysis
36. Appendix
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
